Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Adults Who is COVID-19 naïve or Had Previous COVID-19 Infection or Completed Inactivated or mRNA COVID-19 Vaccination.

NCT05305300 is registered in ClinicalTrials.gov with Yisheng Biopharma (Singapore) Pte. Ltd. as lead sponsor.

NCT NCT05305300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05305300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Adults Who is COVID-19 naïve or Had Previous COVID-19 Infection or Completed Inactivated or mRNA COVID-19 Vaccination.
Lead sponsor
Yisheng Biopharma (Singapore) Pte. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 18, 2021
Completion date
September 15, 2022
Enrollment
135 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic